An SpC editor targeting pre-mRNA splicing for precise CRISPR control and enhanced antitumor efficacy
Nucleic Acids Research · 2025
DOI: 10.1093/nar/gkaf1328 ↗Kurz gefasst
Fachartikel in der Zeitschrift Nucleic Acids Research, 2025. Verfasst von Xiaorui Shi und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Oncology, The Second Affiliated Hospital of Xi'an Jiaotong University, Xi'an, Shaanxi 710004, China. Hauptthemen laut MEDLINE: CRISPR-Cas Systems, Gene Editing, RNA Precursors, RNA Splicing. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 29 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: National Natural Science Foundation of China, Natural Science Basic Research Program of Shaanxi, Guangdong Basic and Applied Basic Research Foundation.
Abstract (Originalsprache)
The CRISPR/Cas9 system is a powerful genome editing tool that has the potential to be applied to a variety of biomedical applications. Despite the considerable potential of this gene editing technology, there are numerous safety concerns including the possibility of unpredictable off-target effects. The splicing process, which involves the removal of introns from pre-mRNA and the alignment of exons to produce mature transcripts, is a critical step in gene expression in most eukaryotes. In this study, we present a spliceosome-responsive CRISPR/Cas9 (SpC) editor that utilizes the splicing inhibitor pladienolide B (PB) to regulate pre-mRNA splicing and control the expression of the anti-CRISPR protein AcrIIA4, thereby modulating the activity of the Cas9 nuclease. This approach allows for precise regulation of the gene editing process, thereby effectively mitigating off-target effects. The reliability and robustness of the SpC editor were demonstrated through in vitro and in vivo bioluminescence imaging. Furthermore, a dual-target sgRNA was designed to target the diphtheria toxin A gene, resulting in apoptosis induction and growth inhibition of tumor cells across various types of cancer cells. Our results indicate that this SpC editor has the capacity to precisely regulate tumor cell growth, thus providing new insights and significant implications for cancer gene therapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Medical Oncology, The Second Affiliated Hospital of Xi'an Jiaotong University, Xi'an, Shaanxi 710004, China.
- Engineering Research Center of Molecular and Neuroimaging, Ministry of Education, School of Life Science and Technology, Xidian University, Xi'an 710071, China.
- Institute of Medical Engineering, School of Basic Medical Sciences, Xi'an Jiaotong University, Xi'an 710061, China.
ORCID-Profile: Fu Wang
Förderung
- National Natural Science Foundation of China
- Natural Science Basic Research Program of Shaanxi
- Guangdong Basic and Applied Basic Research Foundation
Zitieren
APA
Shi, X., Hu, C., Jia, L., Lei, Z., Guo, B., Zhou, J., & Wang, F. (2025). An SpC editor targeting pre-mRNA splicing for precise CRISPR control and enhanced antitumor efficacy. Nucleic Acids Research. https://doi.org/10.1093/nar/gkaf1328
Vancouver
Shi X, Hu C, Jia L, Lei Z, Guo B, Zhou J, et al. An SpC editor targeting pre-mRNA splicing for precise CRISPR control and enhanced antitumor efficacy. Nucleic Acids Research. 2025. doi:10.1093/nar/gkaf1328
BibTeX
@article{Shi2025,
author = {Shi, Xiaorui and Hu, Chong and Jia, Lijun and Lei, Zhen and Guo, Bin and Zhou, Jie and Wang, Fu},
title = {An SpC editor targeting pre-mRNA splicing for precise CRISPR control and enhanced antitumor efficacy},
journal = {Nucleic Acids Research},
year = {2025},
doi = {10.1093/nar/gkaf1328}
}
EUVIMED